Galmed and Barcode Nanotech Develop Heart-Targeting Aramchol Formula

Traditional formulations of Aramchol typically see 80% to 90% of the drug accumulate in the liver, leaving little therapeutic impact on the heart. By utilizing FDA-approved lipids and an AI-enabled screening platform, the companies successfully redirected the drug's biodistribution. This platform allows for the rapid testing of hundreds of nanoparticle candidates to identify those capable of engaging specific disease-driving cells, such as cardiac fibroblasts.

Cardiac fibrosis remains a significant medical challenge, contributing to the progression of heart failure in millions of patients globally. The collaboration hopes to establish a new standard for disease-modifying therapies in cardiovascular medicine. While Galmed continues to focus on its gastrointestinal oncology portfolio, including the commercialization of CG-100, this development represents a strategic expansion into cardiometabolic disease, potentially laying the groundwork for a broader generation of targeted cardiac treatments.